NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 18 January 2022 09:30am

**Location:** Zoom Video Conference

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Prof Abdallah Al-Mohammad Present for items 1 to 4.2.2
4. Alan Thomas Present for all items
5. Ana Duarte Present for all items
6. Andrew Champion Present for all items
7. Dr Craig Buckley Present for all items
8. Dominic Pivonka Present for all items
9. Dr Fiona MacPherson-Smith Present for all items
10. Prof G.J. Melendez-Torres Present for all items
11. Hugo Pedder Present for all items
12. Dr Justin Daniels Present for all items
13. Prof Khalida Ismail Present for all items
14. Dr Michael Holmes Present for all items
15. Min Ven Teo Present for all items
16. Dr Mohit Sharma Present for all items
17. Dr Peter Baker-Gulliver Present for all items
18. Richard Ballerand Present for all items
19. Dr Rita Faria Present for all items
20. Dr Steve Edwards Present for all items

NICE staff present

James Devine, Coordinator Present for all items

Thomas Feist, Project manager Present for all items

Janet Robertson, Associate director Present for items 1 to 4

Joanna Richardson, Technical adviser Present for items 1 to 4

Albany Meikle, Technical analyst Present for items 1 to 4

Shonagh D’Sylva, Project manager Present for item 5

Henry Edwards, Associate director Present for item 5

Adam Storrow, Resource impact Present for all items

David Tyldesley, Resource impact Present for items 1 to 4

Laura Kelly, Administrator Present for all items

Catherine Pank, Assistant project Present for all items

manager

Stephen Norton, HTA analyst Present for all items

Ella Livingstone, HTA adviser Present for all items

Lizzie Walker, HTA analyst (observer) Present for all items

Lucinda Evans, Coordinator Present for all items

Lyn Davies, Coordinator Present for all items

Rumana Zaman, Administrator Present for all items

Matthew Brown, Digital media manager Present for all items

Alexandra Sampson, HTA analyst Present for all items

Haider Shamsi, Associate HTA Present for all items

analyst

Helen Barnett, Senior medical editor Present for all items

**ERG Members Present:**

Karen Pickett, Southampton Health Present for items 1 to 4.2.1

Technology Assessment Centre (SHTAC)

Keith Cooper, Southampton Health Present for items 1 to 4.2.1

Technology Assessment Centre (SHTAC)

Clinical And Patient Experts Present

Beverley Burbridge, Patient expert Present for items 1 to 4.2.1

Kenneth Clare, Patient expert Present for items 1 to 4.2.1

Sarah le Brocq, Patient expert Present for items 1 to 4.2.1

Carel le Roux, Clinical expert Present for items 1 to 4.2.1

John Wilding, Clinical expert Present for items 1 to 4.2.1

Gary McVeigh, NHS England expert Present for items 1 to 4.2.1

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Jane Adam, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr David Maudgil, Dr Roger Whittaker, Sarah Parry, and Dr Sumithra Maheswaran.

### News and announcements

* 1. List any other business or record ‘none’.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 7 December 2021

### Appraisal of Semaglutide for managing overweight and obesity [ID3850]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from Novo Nordisk
     2. The chair asked all committee members, clinical and patient experts, external group representatives, and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Michael Holmes, committee member, declared the following non-personal financial interest: I am presently collaborating with Novo Nordisk (and the group I work with has previously collaborated with GSK) in academic research investigating therapeutic targets using human genetics and exploring the effects of the proteome on risk factors and disease. I have received no personal funds - it is purely an academic collaboration where the companies have paid for services (e.g. statistician time) and/or assays (e.g. proteomics) in a biobank hosted at University of Oxford. I am also a consultant to Boehringer Ingelheim where I advise on the pharmacogenetic interpretations of a therapy that lowers weight - this is done without receiving honoraria or any personal payments whatsoever, in strict accordance with the rules of the CTSU (clinical trial services unit) at the University of Oxford.  
  - It was agreed that these declarations would not prevent Dr Holmes from participating in this discussion.
* Professor Carel le Roux, clinical expert, declared the following interests: direct, financial interest: I serve on the global advisory boards for the below companies and have also received honorariums for speaker events from Novo Nordisk, Boehringer Ingelheim, Herbalife, Johnson & Johnson, GI Dynamics and Keyron. Direct, non-financial interest: A director of the Irish Society for Clinical Nutrition and Metabolism (IrSPEN) and have contributed to patient organisations including the Irish Coalition for People living with Obesity (ICPO). I am the coordinator of a European Union project SOPHIA, interested in reshaping the narrative around obesity as a disease.  
  - It was agreed that these declarations would not prevent Professor le Roux from participating in this discussion
* Professor John Wilding, clinical expert, declared the following interests: direct, financial interest: received honoraria / lecture fees from AstraZeneca, Boehringer Ingelheim, Lilly, Napp, Novo Nordisk, Mundipharma, Sanofi and Takeda. I have undertaken paid editorial work Springer Nature (Medicine Matters Diabetes website) and have also been paid for lectures / webinars by Medscape. Indirect, financial interest: I undertake consultancy for industry contracted via the University of Liverpool (no personal payment) in relation to obesity and type 2 diabetes. In the last 12 months I have undertaken work for AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Napp, Novo Nordisk, Mundipharma, Rhythm Pharmaceuticals, Sanofi, and Saniona. I am a named grantholder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk. Direct, non-financial interest: president of the World Obesity Federation, and a member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA and Society for Endocrinology. I am a member of the Rank Prize Funds Nutrition Committee. I am a member of the steering committee for a tier 3 obesity audit being set up via the Society for Endocrinology via a grant from Novo Nordisk (all unpaid positions).  
  - It was agreed that these declarations would not prevent Professor Wilding from participating in the discussion.
* Sarah le Brocq, patient expert, declared the following interests: I have taken part in some Novo Nordisk internal meetings sharing my experiences of living with obesity with their employees. I am also a Disease Experience Expert Panel (DEEP) member for Novo Nordisk, so have taken part in a number of lived experience presentations in this role too. I was also involved in the Liraglutide TA. I am a Trustee of the Association for the Study of Obesity  
  - It was agreed that these declarations would not prevent her from participating in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the Chair and Lead Team, Dr Jane Adam, Prof. G.J. Melendez-Torres and Richard Ballerand.
  1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
  2. Further updates will be available on the NICE webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10765>

### Evaluation of Appraisal of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828] – ACM2 (part 2 only)

* 1. Part 1 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to not present at this meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10708>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 15 February 2022 and will start promptly at 09:30am.